Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Loriot

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2021
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetateY Loriot, K Fizazi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2025
The next-generation of nectin-4 targeted therapiesC Pobel, Y Loriot
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?Y Loriot, P Mordant, E Deutsch
Bulletin Du Cancer|December 26, 2009
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]D Planchard, Y Loriot, B Besse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2012
Recent developments in treatments targeting castration-resistant prostate cancer bone metastasesY Loriot, C Massard, K Fizazi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2022
FIGHT against FGF/FGFR alterations: what are the next steps?A Bayle, P Martin-Romano, Y Loriot
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Expanding role of chemotherapy in lung cancerY Loriot, J-C Soria, T Le Chevalier
Bulletin Du Cancer|December 26, 2009
[Targeting KRAS pathway in NSCLC therapy]S Le Moulec, Y Loriot, J-C Soria
Lancet (London, England)|August 30, 2008
MVP and vinorelbine for malignant pleural mesotheliomaP Mordant, Y Loriot, J C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Novel and bone-targeted agents for CRPCK Fizazi, L Albiges, C Massard, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2021
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetateY Loriot, K Fizazi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2025
The next-generation of nectin-4 targeted therapiesC Pobel, Y Loriot
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?Y Loriot, P Mordant, E Deutsch
Bulletin Du Cancer|December 26, 2009
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]D Planchard, Y Loriot, B Besse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2012
Recent developments in treatments targeting castration-resistant prostate cancer bone metastasesY Loriot, C Massard, K Fizazi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2022
FIGHT against FGF/FGFR alterations: what are the next steps?A Bayle, P Martin-Romano, Y Loriot
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Expanding role of chemotherapy in lung cancerY Loriot, J-C Soria, T Le Chevalier
Bulletin Du Cancer|December 26, 2009
[Targeting KRAS pathway in NSCLC therapy]S Le Moulec, Y Loriot, J-C Soria
Lancet (London, England)|August 30, 2008
MVP and vinorelbine for malignant pleural mesotheliomaP Mordant, Y Loriot, J C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Novel and bone-targeted agents for CRPCK Fizazi, L Albiges, C Massard, et al.
Pageof 8